期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

高选择性COX-2抑制剂罗非昔布撤市分析 被引量：3

Analysis of withdrawal of rofecoxib-cyclooxygenase-2 specific inhibitor
下载PDF
导出
摘要 罗非昔布是高选择性环氧化酶(COX -2 )抑制剂,用于治疗骨关节炎,控制成人锐痛和痛经。2 0 0 4年9月30日,默克公司宣布在全球范围内主动撤回罗非昔布。本文从高选择性COX 2抑制剂的药理作用与作用机制、罗非昔布的作用特点、临床前及临床研究、不良反应等方面对罗非昔布的撤市做一分析。 Rofecoxib, a COX-2 specific inhibitor, is approved for treatment of osteoarthritis, acute pain and primary dysmenorrhea. On September 30, 2004, Merck announced the voluntary worldwide withdrawal of rofecoxib (Vioxx). This paper reviewed the pharmacological actions of the COX-2 specific inhibitors and the characterization, premarket study, clinical application and side-effects of rofecoxib and analyzed the withdrawal of rofecoxib.
作者 李芹 王睿 陈騉
机构地区 中国人民解放军总医院临床药理研究室
出处 《中国临床药理学与治疗学》 CAS CSCD 2005年第3期259-264,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 罗非昔布 塞来昔布 COX-2抑制剂 心血管事件 撤市 rofecoxib celecoxib COX-2 inhibitor cardiovascular effect withdrawal
分类号 R966 [医药卫生—药理学]
  • 相关文献

参考文献32

  • 1Hawkey CJ. COX-2 inhibitors[J]. Lancet, 1999;353:307- 14
  • 2Ehrich EW, Dallob A, Lepeleire ID, Van HA, Riendeau D,Yuan W, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dentalmodel[J]. Clin Pharmacol Ther, 1999;65:336-47
  • 3Paulson SK, Hribar JD, Liu NWK, Hajdu E, Bible RH, Jr Piergies A, et al. Metabolism and excretion of (14C) celecoxib in healthy male volunteers [J]. Drug Metab Dispos, 2000; 28:308- 14
  • 4Karim A, Tolbert D, Burton E. SC-58635 (celecoxib): a highly selective inhibition of cyclooxygenase-2 disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation[J]. Pharm Res, 1997; 14:S617 - 26
  • 5Scott LJ, Lamb HM. Rofecoxib [J]. Drugs, 1999;58:499-505
  • 6Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W,Ethier D, et al. Rofecoxib [Vioxx, MK-0966:4-(4'-methyls ulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles [J]. J Pharmacol Exp Ther, 1999; 290: 551 -60
  • 7Day R, Morrison B, Luza A. A randomized trail of efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with OA[J]. Arch Int Med, 2000;161:1781 - 7
  • 8Ehrich EW, Schnitzer TJ, Mcllwain H, Levy R, Wolfe F,Weisman M, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee a 6 week double blind, placebo controlled pilot study of rofecoxib[J]. J Rheum, 1999;26:2438 -47
  • 9Fung HB, Kirschenbaum HL. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis[J]. Clin Ther, 1999;21:1131- 57
  • 10Mehlisch DR, Mills S. Ex viro assay of COX-2 inhibitation predicts efficacy in post-surgical dental pain with MK-966[J].Clin Pharmacol Ther, 1998; 63:139 - 45

同被引文献68

  • 1王奇,鞠名达,张威廉.体外循环心脏手术对机体免疫功能的影响[J].中华胸心血管外科杂志,1995,11(6):326-328. 被引量：14
  • 2孙敬华.环氧化酶抑制剂抗肿瘤作用的研究进展[J].中国矫形外科杂志,2005,13(19):1505-1507. 被引量：3
  • 3和芳,张泰昌.老年人非甾体抗炎药相关上消化道出血的临床特征[J].中华消化内镜杂志,2006,23(1):56-58. 被引量：27
  • 4Bresalier RS, Sandier RS, Quan H, etal. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial[J].N Engl J Med, 2005, 352(11) : 1092- 1102.
  • 5Solomon SD, McMurray JV, Pfefer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention [J]. N Engl J Med, 2005, 352 (11): 1071-1080.
  • 6Castro MR, Edelman JL, et al. Effect of COX inhibitor on VEGF2 induced retinal vascular leakage and experimental corneal and choroidal neovascularization[J].Exp Eye Res, 2004, 79(2): 275-285.
  • 7Buerkle MA, Lehrer S, Sohn HY, et al. Selective Inhibition of eyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo [J]. Circulation, 2004, 110 (14) : 2053-2059.
  • 8Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhihitors and their effects on blood pressure [J]. Arch Intern Med, 2005, 165 (5): 490-496.
  • 9Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus [J]. Arch Intern Med, 2005, 165 (2):161-168.
  • 10Dowd NP, Seully M, Adderley SR, et al. Inhibition of cyelooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo[J].J Clin Invest, 2001, 108(4): 585-590.

引证文献3

二级引证文献16

中国临床药理学与治疗学
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部